Vaxart Discusses Reverse Stock Split and Capital Raise

An update from Vaxart ( (VXRT) ) is now available.

On May 28, 2025, Vaxart, Inc. addressed additional frequently asked questions from retail investors regarding a proposed reverse stock split, which is to be voted on at their Annual Meeting on June 2, 2025. The company emphasized the importance of the reverse stock split to regain compliance with Nasdaq listing requirements, as failure to do so could result in delisting. Vaxart also highlighted its strategic decision to raise capital through a $40 million offering to extend its cash runway and advance its clinical programs, despite having an at-the-market offering in place. The company reassured investors that the reverse stock split would not inherently increase short selling or cause dilution and remains committed to exploring partnerships to support its vaccine development efforts.

The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s stock score is primarily driven by strong revenue growth and strategic initiatives such as clinical trial advancements and the proposed reverse stock split. However, significant challenges in profitability, cash flow management, and technical indicators suggest bearish momentum. The risk of NASDAQ delisting also weighs heavily on the stock. While strategic initiatives and cash management efforts offer some hope for future stability, current risks remain substantial.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart, Inc. is a biotechnology company based in South San Francisco, California, focusing on the development of oral vaccines. The company is known for its innovative oral pill vaccine platform targeting infectious diseases such as norovirus, COVID-19, and influenza.

Average Trading Volume: 1,848,151

Technical Sentiment Signal: Sell

Current Market Cap: $105.2M

For an in-depth examination of VXRT stock, go to TipRanks’ Stock Analysis page.